These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Physiologic evidence for the efficacy of positive expiratory pressure as an airway clearance technique in patients with cystic fibrosis. Darbee JC, Ohtake PJ, Grant BJ, Cerny FJ. Phys Ther; 2004 Jun; 84(6):524-37. PubMed ID: 15161418 [Abstract] [Full Text] [Related]
32. Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Johnson CA, Butler SM, Konstan MW, Breen TJ, Morgan WJ. J Pediatr; 1999 Jun; 134(6):734-9. PubMed ID: 10356143 [Abstract] [Full Text] [Related]
35. [Pharmacological and clinical profiles of Dornase alfa (Pulmozyme®) in the management of cystic fibrosis patients to improve pulmonary function]. Kokubo H, Hosatani S, Ichikawa M. Nihon Yakurigaku Zasshi; 2013 Apr; 141(4):213-9. PubMed ID: 23575427 [No Abstract] [Full Text] [Related]
36. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group. Geller DE, Eigen H, Fiel SB, Clark A, Lamarre AP, Johnson CA, Konstan MW. Pediatr Pulmonol; 1998 Feb; 25(2):83-7. PubMed ID: 9516090 [Abstract] [Full Text] [Related]
39. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics. Pirzada OM, McGaw J, Taylor CJ, Everard ML. J Cyst Fibros; 2003 Jun; 2(2):69-71. PubMed ID: 15463852 [Abstract] [Full Text] [Related]